1
|
Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon‐Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan‐Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T. LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO Mol Med 2023; 15:e17719. [PMID: 37966164 PMCID: PMC10701601 DOI: 10.15252/emmm.202317719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 10/16/2023] [Accepted: 10/23/2023] [Indexed: 11/16/2023] Open
Abstract
Metastatic uveal melanomas are highly resistant to all existing treatments. To address this critical issue, we performed a kinome-wide CRISPR-Cas9 knockout screen, which revealed the LKB1-SIK2 module in restraining uveal melanoma tumorigenesis. Functionally, LKB1 loss enhances proliferation and survival through SIK2 inhibition and upregulation of the sodium/calcium (Na+ /Ca2+ ) exchanger SLC8A1. This signaling cascade promotes increased levels of intracellular calcium and mitochondrial reactive oxygen species, two hallmarks of cancer. We further demonstrate that combination of an SLC8A1 inhibitor and a mitochondria-targeted antioxidant promotes enhanced cell death efficacy in LKB1- and SIK2-negative uveal melanoma cells compared to control cells. Our study also identified an LKB1-loss gene signature for the survival prognostic of patients with uveal melanoma that may be also predictive of response to the therapy combination. Our data thus identify not only metabolic vulnerabilities but also new prognostic markers, thereby providing a therapeutic strategy for particular subtypes of metastatic uveal melanoma.
Collapse
Affiliation(s)
- Sarah Proteau
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Imène Krossa
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Chrystel Husser
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | | | - Federica Sella
- Department of Dermatology, University Hospital ZurichUniversity of ZurichZurichSwitzerland
| | - Karine Bille
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | | | - Mélanie Dalmasso
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Thibault Barouillet
- Inserm, Hematometabolism and metainflammation, team 13, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Yann Cheli
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Céline Pisibon
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Nicole Arrighi
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Sacha Nahon‐Estève
- University Côte d'AzurNiceFrance
- Department of OphthalmologyCentre Hospitalier Universitaire of NiceNiceFrance
| | - Arnaud Martel
- University Côte d'AzurNiceFrance
- Department of OphthalmologyCentre Hospitalier Universitaire of NiceNiceFrance
| | | | - Sandra Lassalle
- University Côte d'AzurNiceFrance
- Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d'Azur University, Biobank BB‐0033‐00025, IRCAN team 4, OncoAge FHUNiceFrance
| | | | - Patrick Brest
- University Côte d'AzurNiceFrance
- IRCAN team 4, Inserm, CNRS, FHU‐oncoAge, IHU‐RESPIRera NiceNiceFrance
| | - Nathalie M Mazure
- University Côte d'AzurNiceFrance
- Inserm, Cancer, Metabolism and environment, team, Equipe labellisée Ligue 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Frédéric Bost
- University Côte d'AzurNiceFrance
- Inserm, Cancer, Metabolism and environment, team, Equipe labellisée Ligue 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Stéphanie Baillif
- University Côte d'AzurNiceFrance
- Department of OphthalmologyCentre Hospitalier Universitaire of NiceNiceFrance
| | - Solange Landreville
- Département d'ophtalmologie et d'ORL‐CCF, Faculté de médecineUniversité LavalQuebec CityQCCanada
- CUO‐Recherche and Axe médecine régénératriceCentre de recherche du CHU de Québec‐Université LavalQuebec CityQCCanada
- Centre de recherche sur le cancer de l'Université LavalQuebec CityQCCanada
- Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEXQuebec CityQCCanada
| | - Simon Turcotte
- Cancer AxisCentre de recherche du Centre Hospitalier de l'Université de Montréal/Institut du cancer de MontréalMontréalQCCanada
- Hepato‐Pancreato‐Biliary Surgery and Liver Transplantation ServiceCentre hospitalier de l'Université de MontréalMontréalQCCanada
| | - Dan Hasson
- Department of Oncological Sciences, Tisch Cancer InstituteIcahn School of Medicine at Mount SinaiNew YorkNYUSA
- Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) FacilityIcahn School of Medicine at Mount SinaiNew YorkNYUSA
| | - Saul Carcamo
- Department of Oncological Sciences, Tisch Cancer InstituteIcahn School of Medicine at Mount SinaiNew YorkNYUSA
- Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) FacilityIcahn School of Medicine at Mount SinaiNew YorkNYUSA
| | | | - Emily Bernstein
- Department of Oncological Sciences, Tisch Cancer InstituteIcahn School of Medicine at Mount SinaiNew YorkNYUSA
| | - Laurent Yvan‐Charvet
- University Côte d'AzurNiceFrance
- Inserm, Hematometabolism and metainflammation, team 13, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Mitchell P Levesque
- Department of Dermatology, University Hospital ZurichUniversity of ZurichZurichSwitzerland
| | - Robert Ballotti
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Corine Bertolotto
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| | - Thomas Strub
- University Côte d'AzurNiceFrance
- Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, and Equipe labellisée ARC 2022, Mediterranean Centre for Molecular MedicineNiceFrance
| |
Collapse
|
2
|
Pandiani C, Strub T, Nottet N, Cheli Y, Gambi G, Bille K, Husser C, Dalmasso M, Béranger G, Lassalle S, Magnone V, Pédeutour F, Irondelle M, Maschi C, Nahon-Estève S, Martel A, Caujolle JP, Hofman P, LeBrigand K, Davidson I, Baillif S, Barbry P, Ballotti R, Bertolotto C. Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. Cell Death Differ 2021; 28:1990-2000. [PMID: 33462406 PMCID: PMC8185008 DOI: 10.1038/s41418-020-00730-7] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 12/27/2020] [Accepted: 12/29/2020] [Indexed: 01/30/2023] Open
Abstract
Intratumor heterogeneity has been recognized in numerous cancers as a major source of metastatic dissemination. In uveal melanomas, the existence and identity of specific subpopulations, their biological function and their contribution to metastasis remain unknown. Here, in multiscale analyses using single-cell RNA sequencing of six different primary uveal melanomas, we uncover an intratumoral heterogeneity at the genomic and transcriptomic level. We identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of the samples. We also decipher a gene regulatory network underlying an invasive and poor prognosis state driven in part by the transcription factor HES6. HES6 heterogenous expression has been validated by RNAscope assays within primary human uveal melanomas, which further unveils the existence of these cells conveying a dismal prognosis in tumors diagnosed with a favorable outcome using bulk analyses. Depletion of HES6 impairs proliferation, migration and metastatic dissemination in vitro and in vivo using the chick chorioallantoic membrane assay, demonstrating the essential role of HES6 in uveal melanomas. Thus, single-cell analysis offers an unprecedented view of primary uveal melanoma heterogeneity, identifies bona fide biomarkers for metastatic cells in the primary tumor, and reveals targetable modules driving growth and metastasis formation. Significantly, our findings demonstrate that HES6 is a valid target to stop uveal melanoma progression.
Collapse
Affiliation(s)
- Charlotte Pandiani
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Thomas Strub
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Nicolas Nottet
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Yann Cheli
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Giovanni Gambi
- grid.420255.40000 0004 0638 2716Department of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France
| | - Karine Bille
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Chrystel Husser
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Mélanie Dalmasso
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Guillaume Béranger
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Sandra Lassalle
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Laboratoire de Pathologie clinique et expérimentale, biobanque BB-0033-00025, and IRCAN team 4, FHU OncoAge, Nice, France
| | - Virginie Magnone
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.429194.30000 0004 0638 0649CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Florence Pédeutour
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.464719.90000 0004 0639 4696Laboratoire de Génétique des tumeurs solides and IRCAN, Nice, France
| | - Marie Irondelle
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Imagery platform, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Célia Maschi
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Pasteur 2 Teaching Hospital, Department of Ophthalmology, Nice, France
| | - Sacha Nahon-Estève
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Pasteur 2 Teaching Hospital, Department of Ophthalmology, Nice, France
| | - Arnaud Martel
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Pasteur 2 Teaching Hospital, Department of Ophthalmology, Nice, France
| | - Jean-Pierre Caujolle
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Pasteur 2 Teaching Hospital, Department of Ophthalmology, Nice, France
| | - Paul Hofman
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Laboratoire de Pathologie clinique et expérimentale, biobanque BB-0033-00025, and IRCAN team 4, FHU OncoAge, Nice, France
| | - Kévin LeBrigand
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.429194.30000 0004 0638 0649CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Irwin Davidson
- grid.420255.40000 0004 0638 2716Department of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France
| | - Stéphanie Baillif
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,Pasteur 2 Teaching Hospital, Department of Ophthalmology, Nice, France
| | - Pascal Barbry
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.429194.30000 0004 0638 0649CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Robert Ballotti
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| | - Corine Bertolotto
- grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Nice, France ,grid.462370.40000 0004 0620 5402Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
| |
Collapse
|
3
|
Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R. Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer 2021; 20:21. [PMID: 33504341 PMCID: PMC7839296 DOI: 10.1186/s12943-021-01319-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Yann Cheli
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France.
| | - Meri K Tulic
- Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France
| | - Najla El Hachem
- Laboratory of Cancer Signaling, University of Liège, Liège, Belgium
| | - Nicolas Nottet
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Arnaud Jacquel
- Université Nice Côte d'Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000, Nice, France
| | - Maeva Gesson
- Université Nice Côte d'Azur, INSERM, U1065, Imaging platform, 06000, Nice, France
| | - Thomas Strub
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Karine Bille
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | | | | | - Guillaume E Beranger
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France.,Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France
| | - Thierry Passeron
- Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France.,CHU NICE, Département de Dermatologie, 06000, Nice, France
| | - Pierre Close
- Laboratory of Cancer Signaling, University of Liège, Liège, Belgium
| | - Corine Bertolotto
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Robert Ballotti
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| |
Collapse
|
4
|
Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer 2021; 20:12. [PMID: 33413419 PMCID: PMC7789764 DOI: 10.1186/s12943-020-01306-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 12/29/2020] [Indexed: 02/08/2023] Open
Abstract
Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies. Similar phenotypes have been more recently also linked to resistance to immune checkpoint therapies. We demonstrated here that the loss of MIcrophthalmia associated Transcription Factor (MITF), a pivotal player in melanocyte differentiation, favors the escape of melanoma cells from the immune system. We identified Integrin beta-like protein 1 (ITGBL1), a secreted protein, upregulated in anti-PD1 resistant patients and in MITFlow melanoma cells, as the key immunomodulator. ITGBL1 inhibited immune cell cytotoxicity against melanoma cells by inhibiting NK cells cytotoxicity and counteracting beneficial effects of anti-PD1 treatment, both in vitro and in vivo. Mechanistically, MITF inhibited RUNX2, an activator of ITGBL1 transcription. Interestingly, VitaminD3, an inhibitor of RUNX2, improved melanoma cells to death by immune cells. In conclusion, our data suggest that inhibition of ITGBL1 might improve melanoma response to immunotherapies.
Collapse
Affiliation(s)
- Yann Cheli
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France.
| | - Meri K Tulic
- Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France
| | - Najla El Hachem
- Laboratory of Cancer Signaling, University of Liège, Liège, Belgium
| | - Nicolas Nottet
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Arnaud Jacquel
- Université Nice Côte d'Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000, Nice, France
| | - Maeva Gesson
- Université Nice Côte d'Azur, INSERM, U1065, Imaging platform, 06000, Nice, France
| | - Thomas Strub
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Karine Bille
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | | | | | - Guillaume E Beranger
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
- Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France
| | - Thierry Passeron
- Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France
- CHU NICE, Département de Dermatologie, 06000, Nice, France
| | - Pierre Close
- Laboratory of Cancer Signaling, University of Liège, Liège, Belgium
| | - Corine Bertolotto
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| | - Robert Ballotti
- Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France
| |
Collapse
|
5
|
Gaudel C, Soysouvanh F, Leclerc J, Bille K, Husser C, Montcriol F, Bertolotto C, Ballotti R. Regulation of Melanogenesis by the Amino Acid Transporter SLC7A5. J Invest Dermatol 2020; 140:2253-2259.e4. [PMID: 32240722 DOI: 10.1016/j.jid.2020.03.941] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 02/26/2020] [Accepted: 03/09/2020] [Indexed: 10/24/2022]
Abstract
Integration of chromatin immunoprecipitation-sequencing and microarray data enabled us to identify previously unreported MITF-target genes, among which the amino acid transporter SLC7A5 is also included. We reported that small interfering RNA-mediated SLC7A5 knockdown decreased pigmentation in B16F10 cells but neither affected morphology nor dendricity. Treatment with the SLC7A5 inhibitors 2-amino-2-norbornanecarboxylic acid (BCH) or JPH203 also decreased melanin synthesis in B16F10 cells. Our findings indicated that BCH was as potent as reference depigmenting agent, kojic acid, but acted through a different pathway not affecting tyrosinase activity. BCH also decreased pigmentation in human MNT1 melanoma cells or normal human melanocytes. Finally, we tested BCH on a more physiological model, using reconstructed human epidermis and confirmed a strong inhibition of pigmentation, revealing the clinical potential of SLC7A5 inhibition and positioning BCH as a depigmenting agent suitable for cosmetic or dermatological intervention in hyperpigmentation diseases.
Collapse
Affiliation(s)
- Céline Gaudel
- Nunii Laboratoire, Grasse Biotech, Grasse, France; Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | - Frédéric Soysouvanh
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | - Justine Leclerc
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | - Karine Bille
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | - Chrystel Husser
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | | | - Corine Bertolotto
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France
| | - Robert Ballotti
- Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.
| |
Collapse
|
6
|
Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, Mograbi B, Rocchi S, Yvan-Charvet L, Ballotti R, Bertolotto C. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev 2018; 32:448-461. [PMID: 29567766 PMCID: PMC5900716 DOI: 10.1101/gad.305854.117] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 03/05/2018] [Indexed: 12/19/2022]
Abstract
In BRAFV600E melanoma cells, a global metabolomic analysis discloses a decrease in nicotinamide adenine dinucleotide (NAD+) levels upon PLX4032 treatment that is conveyed by a STAT5 inhibition and a transcriptional regulation of the nicotinamide phosphoribosyltransferase (NAMPT) gene. NAMPT inhibition decreases melanoma cell proliferation both in vitro and in vivo, while forced NAMPT expression renders melanoma cells resistant to PLX4032. NAMPT expression induces transcriptomic and epigenetic reshufflings that steer melanoma cells toward an invasive phenotype associated with resistance to targeted therapies and immunotherapies. Therefore, NAMPT, the key enzyme in the NAD+ salvage pathway, appears as a rational target in targeted therapy-resistant melanoma cells and a key player in phenotypic plasticity of melanoma cells.
Collapse
Affiliation(s)
- Mickaël Ohanna
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Mickaël Cerezo
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Nicolas Nottet
- Université Nice Côte d'Azur, INSERM, C3M, 06204 Nice, France
| | - Karine Bille
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Robin Didier
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Guillaume Beranger
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Baharia Mograbi
- U1081, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Equipe Labellisée ARC, Université Nice Côte d'Azur, UMR7284, Centre National de la Recherche Scientifique (CNRS), 06107 Nice, France
| | - Stéphane Rocchi
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Laurent Yvan-Charvet
- U1065, INSERM, Team ATIP-Avenir, Université Nice Côte d'Azur, INSERM, C3M, 06204 Nice, France
| | - Robert Ballotti
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| | - Corine Bertolotto
- U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France
| |
Collapse
|
7
|
Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression. J Natl Cancer Inst 2017; 109:3071266. [PMID: 28376192 DOI: 10.1093/jnci/djw340] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Accepted: 12/22/2016] [Indexed: 01/20/2023] Open
Abstract
Background MITF encodes an oncogenic lineage-specific transcription factor in which a germline mutation ( MITFE318K ) was identified in human patients predisposed to both nevus formation and, among other tumor types, melanoma. The molecular mechanisms underlying the oncogenic activity of MITF E318K remained uncharacterized. Methods Here, we compared the SUMOylation status of endogenous MITF by proximity ligation assay in melanocytes isolated from wild-type (n = 3) or E318K (n = 4) MITF donors. We also used a newly generated Mitf E318K knock-in (KI) mouse model to assess the role of Mitf E318K (n = 7 to 13 mice per group) in tumor development in vivo and performed transcriptomic analysis of the tumors to identify the molecular mechanisms. Finally, using immortalized or normal melanocytes (wild-type or E318K MITF, n = 2 per group), we assessed the role of MITF E318K on the induction of senescence mediated by BRAF V600E . All statistical tests were two-sided. Results We demonstrated a decrease in endogenous MITF SUMOylation in melanocytes from MITF E318K patients (mean of cells with hypoSUMOylated MITF, MITF E318K vs MITF WT , 94% vs 44%, difference = 50%, 95% CI = 21.8% to 67.2%, P = .004). The Mitf E318K mice were slightly hypopigmented (mean melanin content Mitf WT vs Mitf E318K/+ , 0.54 arbitrary units [AU] vs 0.36 AU, difference = -0.18, 95% CI = -0.36 to -0.007, P = .04). We provided genetic evidence that Mitf E318K enhances BRaf V600E -induced nevus formation in vivo (mean nevus number for Mitf E318K , BRaf V600E vs Mitf WT , BRaf V600E , 68 vs 44, difference = 24, 95% CI = 9.1 to 38.9, P = .006). Importantly, although Mitf E318K was not sufficient to cooperate with BRaf V600E alone in promoting metastatic melanoma, it accelerated tumor formation on a BRaf V600E , Pten-deficient background (median survival, Mitf E318K/+ = 42 days, 95% CI = 31 to 46 vs Mitf WT = 51 days, 95% CI = 50 to 55, P < .001). Transcriptome analysis suggested a decrease in senescence in tumors from Mitf E318K mice. We confirmed this hypothesis by in vitro experiments, demonstrating that Mitf E318K impaired the ability of human melanocytes to undergo BRAF V600E -induced senescence. Conclusions We characterized the functions of melanoma-associated MITF E318K mutations. Our results demonstrate that MITF E318K reduces the program of senescence to potentially favor melanoma progression in vivo.
Collapse
Affiliation(s)
- Caroline Bonet
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Flavie Luciani
- Center for Human Genetics, KU Leuven, Leuven, Belgium.,Center for the Biology of Disease, VIB, Leuven, Belgium
| | - Jean-François Ottavi
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Justine Leclerc
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | | | - Marina Boncompagni
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Karine Bille
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Véronique Hofman
- University of Nice Sophia-Antipolis, UFR Médecine, Nice, France.,Inserm, ERI21/EA 4319, Nice, France
| | | | | | - Thomas Strub
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS, INSERM, Université de Strasbourg, Illkirch, France
| | - Yann Cheli
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Mickaël Ohanna
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | | | | | - Stéphane Rocchi
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Marie-Christine Birling
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,Institut Clinique de la Souris-Mouse Clinical Institute, Illkirch, France
| | - Marie-Françoise Avril
- AP-HP, Hôpital Cochin -Tarnier, Service de Dermatologie et Faculté Paris Descartes, Paris, France
| | - Nicolas Poulalhon
- Centre Hospitalier Universitaire de Lyon, Department of Dermatology, Lyon, France
| | - Thomas Luc
- Centre Hospitalier Universitaire de Lyon, Department of Dermatology, Lyon, France
| | - Paul Hofman
- University of Nice Sophia-Antipolis, UFR Médecine, Nice, France.,Inserm, ERI21/EA 4319, Nice, France
| | | | - Irwin Davidson
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS, INSERM, Université de Strasbourg, Illkirch, France
| | - Brigitte Bressac-de Paillerets
- Service de Génétique, Institut de Cancérologie Gustave Roussy, Villejuif, France.,INSERM U1186, Immunologie intégrative des tumeurs et génétique oncologique, Paris, France
| | - Robert Ballotti
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| | - Jean-Christophe Marine
- Center for Human Genetics, KU Leuven, Leuven, Belgium.,Center for the Biology of Disease, VIB, Leuven, Belgium
| | - Corine Bertolotto
- INSERM, U1065 (équipe 1), Equipe labélisée ARC 2016, C3M, Nice, France.,University of Nice Sophia-Antipolis, UFR Médecine, Nice, France
| |
Collapse
|
8
|
Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2015; 531:126. [PMID: 26633630 DOI: 10.1038/nature16158] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour JP, Ballotti R, Bertolotto C. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget 2015; 5:2085-95. [PMID: 24742694 PMCID: PMC4039147 DOI: 10.18632/oncotarget.1791] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
SIRT1 operates as both a tumor suppressor and oncogenic factor depending on the cell context. Whether SIRT1 plays a role in melanoma biology remained poorly elucidated. Here, we demonstrate that SIRT1 is a critical regulator of melanoma cell proliferation. SIRT1 suppression by genetic or pharmacological approaches induces cell cycle arrest and a senescence-like phenotype. Gain and loss of function experiments show that M-MITF regulates SIRT1 expression, thereby revealing a melanocyte-specific control of SIRT1. SIRT1 over-expression relieves the senescence-like phenotype and the proliferation arrest caused by MITF suppression, demonstrating that SIRT1 is an effector of MITF-induced proliferation in melanoma cells. Interestingly, SIRT1 level and activity are enhanced in the PLX4032-resistant BRAFV600E-mutated melanoma cells compared with their sensitive counterpart. SIRT1 inhibition decreases melanoma cell growth and rescues the sensibility to PLX4032 of PLX4032-resistant BRAFV600E-mutated melanoma cells. In conclusion, we provide the first evidence that inhibition of SIRT1 warrants consideration as an anti-melanoma therapeutic option.
Collapse
Affiliation(s)
- Mickaël Ohanna
- INSERM, U1065 (équipe 1), Equipe labélisée Ligue Contre le Cancer, C3M, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget 2014; 4:2212-24. [PMID: 24344100 PMCID: PMC3926821 DOI: 10.18632/oncotarget.1143] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Here, we showed that the secretome of senescent melanoma cells drives basal melanoma cells towards a mesenchymal phenotype, with characteristic of stems illustrated by increased level of the prototype genes FN1, SNAIL, OCT4 and NANOG. This molecular reprogramming leads to an increase in the low-MITF and slow-growing cell population endowed with melanoma-initiating cell features. The secretome of senescent melanoma cells induces a panel of 52 genes, involved in cell movement and cell/cell interaction, among which AXL and ALDH1A3 have been implicated in melanoma development. We found that the secretome of senescent melanoma cells activates the STAT3 pathway and STAT3 inhibition prevents secretome effects, including the acquisition of tumorigenic properties. Collectively, the findings provide insights into how the secretome of melanoma cells entering senescence upon chemotherapy treatments increases the tumorigenicity of naïve melanoma cells by inducing, through STAT3 activation, a melanoma-initiating cell phenotype that could favor chemotherapy resistance and relapse.
Collapse
Affiliation(s)
- Mickaël Ohanna
- Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 1, Biologie et pathologies des mélanocytes: de la pigmentation cutanée au mélanome. Equipe labellisée Ligue 2013, Nice, F-06204, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem 2012; 287:29887-98. [PMID: 22767597 DOI: 10.1074/jbc.m112.371682] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Metastatic melanoma is a deadly skin cancer and is resistant to almost all existing treatment. Vemurafenib, which targets the BRAFV600E mutation, is one of the drugs that improves patient outcome, but the patients next develop secondary resistance and a return to cancer. Thus, new therapeutic strategies are needed to treat melanomas and to increase the duration of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor response. The ERK pathway controls cell proliferation, and Aurora B plays a pivotal role in cell division. Here, we confirm that Aurora B is highly expressed in metastatic melanoma cells and that Aurora B inhibition triggers both senescence-like phenotypes and cell death in melanoma cells. Furthermore, we show that the BRAF/ERK axis controls Aurora B expression at the transcriptional level, likely through the transcription factor FOXM1. Our results provide insight into the mechanism of Aurora B regulation and the first molecular basis of Aurora B regulation in melanoma cells. The inhibition of Aurora B expression that we observed in vemurafenib-sensitive melanoma cells was rescued in cells resistant to this drug. Consistently, these latter cells remain sensitive to the effect of the Aurora B inhibitor. Noteworthy, wild-type BRAF melanoma cells are also sensitive to Aurora B inhibition. Collectively, our findings, showing that Aurora B is a potential target in melanoma cells, particularly in those vemurafenib-resistant, may open new avenues to improve the treatment of metastatic melanoma.
Collapse
Affiliation(s)
- Caroline Bonet
- Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 1, Biologie et Pathologies des Mélanocytes de la Pigmentation Cutanée au Mélanome, Nice F-06204, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 2011; 25:1245-61. [PMID: 21646373 DOI: 10.1101/gad.625811] [Citation(s) in RCA: 199] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Melanoma cells can enter the process of senescence, but whether they express a secretory phenotype, as reported for other cells, is undetermined. This is of paramount importance, because this secretome can alter the tumor microenvironment and the response to chemotherapeutic drugs. More generally, the molecular events involved in formation of the senescent-associated secretome have yet to be determined. We reveal here that melanoma cells experiencing senescence in response to diverse stimuli, including anti-melanoma drugs, produce an inflammatory secretory profile, where the chemokine ligand-2 (CCL2) acts as a critical effector. Thus, we reveal how senescence induction might be involved in therapeutic failure in melanoma. We further provide a molecular relationship between senescence induction and secretome formation by revealing that the poly(ADP-ribose) polymerase-1 (PARP-1)/nuclear factor-κB (NF-κB) signaling cascade, activated during senescence, drives the formation of a secretome endowed with protumoral and prometastatic properties. Our findings also point to the existence of the PARP-1 and NF-κB-associated secretome, termed the PNAS, in nonmelanoma cells. Most importantly, inhibition of PARP-1 or NF-κB prevents the proinvasive properties of the secretome. Collectively, identification of the PARP-1/NF-κB axis in secretome formation opens new avenues for therapeutic intervention against cancers.
Collapse
Affiliation(s)
- Mickaël Ohanna
- Biologie et Pathologies des Mélanocytes de la Pigmentation Cutanée au Mélanome, Equipe labellisée Ligue Nationale contre le Cancer, Nice, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A, Hofman V, Hofman P, Ponzio G, Bahadoran P, Ballotti R, Bertolotto C. Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas. Cancer Res 2010; 70:3813-22. [DOI: 10.1158/0008-5472.can-09-2913] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Cheli Y, Luciani F, Khaled M, Beuret L, Bille K, Gounon P, Ortonne JP, Bertolotto C, Ballotti R. {alpha}MSH and Cyclic AMP elevating agents control melanosome pH through a protein kinase A-independent mechanism. J Biol Chem 2009; 284:18699-706. [PMID: 19389708 DOI: 10.1074/jbc.m109.005819] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Melanins are synthesized in melanocytes within specialized organelles called melanosomes. Numerous studies have shown that the pH of melanosome plays a key role in the regulation of melanin synthesis. However, until now, acute regulation of melanosome pH by a physiological stimulus has never been demonstrated. In the present study, we show that the activation of the cAMP pathway by alphaMSH or forskolin leads to an alkalinization of melanosomes and a concomitant regulation of vacuolar ATPases and ion transporters of the solute carrier family. The solute carrier family members include SLC45A2, which is mutated in oculocutaneous albinism type IV, SLC24A4 and SLC24A5, proteins implicated in the control of eye, hair, and skin pigmentation, and the P protein, encoded by the oculocutaneous albinism type II locus. Interestingly, H89, a pharmacological inhibitor of protein kinase A (PKA), prevents the cAMP-induced pigmentation and induces acidification of melanosomes. The drastic depigmenting effect of H89 is not due to an inhibition of tyrosinase expression. Indeed, H89 blocks the induction of melanogenesis induced by LY294002, a potent inhibitor of the PI 3-kinase pathway, without any effect on tyrosinase expression. Furthermore, PKA is not involved in the inhibition of pigmentation promoted by H89 because LY294002 induces pigmentation independently of PKA. Also, other PKA inhibitors do not affect pigmentation. Taken together, our results strengthen the support for a key role of melanosome pH in the regulation of melanin synthesis and, for the first time, demonstrate that melanosome pH is regulated by cAMP and alphaMSH. Notably, these are both mediators of the response to solar UV radiation, the main physiological stimulus of skin pigmentation.
Collapse
Affiliation(s)
- Yann Cheli
- From INSERM, U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Equipe 1, Biology and Pathologies of Melanocytes, F-06204 Nice Cedex 3, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hilmi C, Larribere L, Deckert M, Rocchi S, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C. Involvement of FKHRL1 in melanoma cell survival and death. Pigment Cell Melanoma Res 2008; 21:139-46. [PMID: 18426407 DOI: 10.1111/j.1755-148x.2008.00440.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Melanoma is a highly aggressive tumour characterized by a strong resistance to apoptotic stimuli that give rise to a selective advantage for tumour progression and metastasis formation. Therefore, it is of paramount importance to better understand the mechanisms involved in this resistance to apoptosis. In this report, we focused our attention on FKHRL1, a member of the forkhead family of transcription factors, which controls expression of genes involved in cell cycle progression and apoptosis. In melanoma cells, we show that IGF1, which exerts pro-survival properties, induces the phosphorylation and nuclear exclusion of FKHRL1 in a PI3K/AKT-dependent pathway. Moreover, we observe that over-expression of a non-phosphorylable mutant of FKHRL1 (FKHRL1-TM), constitutively localized to the nucleus, promotes apoptotic cell death of melanoma cells. Finally, we find that FKHRL1-TM decreases the expression of survivin, a member of the inhibitor of apoptosis protein and that survivin re-expression partially rescues the deleterious effects of FKHRL1. Taken together, these findings reveal, in melanoma cells, that endogenous FKHRL1 is a downstream target of the PI3K/AKT pathway and suggest that the phosphorylation of this transcription factor may be involved in the pro-survival effects of growth factors such as IGF1. On the other hand, forced nuclear localization of FKHRL1 decreases melanoma cell growth and may serve as a therapeutic strategy against melanoma.
Collapse
Affiliation(s)
- C Hilmi
- INSERM U597, Biologie et Pathologie des cellules mélanocytaires: de la pigmentation cutanée au mélanome, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Chiaverini C, Beuret L, Flori E, Busca R, Abbe P, Bille K, Bahadoran P, Ortonne JP, Bertolotto C, Ballotti R. Microphthalmia-associated transcription factor regulates RAB27A gene expression and controls melanosome transport. J Biol Chem 2008; 283:12635-42. [PMID: 18281284 DOI: 10.1074/jbc.m800130200] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Melanosomes are lysosome-related organelles specialized in melanin synthesis and transport. In this study, we show that microphthalmia-associated transcription factor (MITF) silencing induces melanosome gathering around the nucleus and causes the relocalization of Rab27A, Slac2a-Mlph, and Myo5a that control the transport of melanosomes on the actin network. In an attempt to elucidate the mechanism by which MITF controls melanosome distribution, we identify RAB27A as a new MITF target gene. Indeed, MITF silencing leads to a dramatic decrease in Rab27A expression and blocks the stimulation of Rab27A expression evoked by cAMP. Further, forced expression of MITF increases Rab27A expression, indicating that MITF is required and sufficient for Rab27A expression in melanoma cells. MITF binds to two E-boxes in the proximal region of the Rab27A promoter and stimulates its transcriptional activity. Finally, re-expression of Rab27A, in MITF-depleted cells, restores the transport of melanosomes to the cell periphery. These results show that RAB27A is a new direct transcriptional target of MITF and link MITF to melanosome transport, another key parameter of melanocyte differentiation and skin pigmentation. Interestingly, Rab27A is involved in other fundamental physiological functions, such as the transport of lytic granules and insulin secretion. Thus our results, deciphering the mechanism of Rab27A transcriptional regulation, have an interest that goes beyond the skin pigmentation field.
Collapse
Affiliation(s)
- Christine Chiaverini
- INSERM U895, Biologie et Pathologies des Cellules Mélanocytaires de la Pigmentation Cutanée au Mélanome 28, avenue de Valombrose, 06107 Nice Cedex 2, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2007; 128:1499-505. [PMID: 18079751 DOI: 10.1038/sj.jid.5701185] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
IGF1 plays a key role in the development and growth of multiple tumors and in the prevention of apoptosis. In melanoma cells, IGF1 has been shown to mediate resistance to anoikis-induced apoptosis. However, the effect of IGF1 on other proapoptotic stimuli has never been reported. Further, the molecular mechanisms by which IGF1 mediates its prosurvival properties in melanoma cells remain unknown. Here, we demonstrate that IGF1 impairs the onset of tumor necrosis factor-related apoptosis-inducing ligand and staurosporine-induced apoptosis in melanoma cells expressing either wild-type or oncogenic B-Raf. Further, we show that IGF1 inhibits mitochondrial damage that occurs during apoptosis, thereby indicating that IGF1 acts at the level of mitochondria to mediate its antiapoptotic stimuli. Accordingly, IGF1 increases the mRNA levels and protein expression of antiapoptotic members of the BCL2 family--BCL2 and BCL-X(L)--and that of the inhibitor of apoptosis protein, survivin. Further, their specific silencing by small interfering RNA prevents the protective effect of IGF1. These findings therefore delineate the molecular mechanisms by which IGF1 mediates its prosurvival properties and provide a basis for clinical strategies designed to neutralize IGF1 or its target genes.
Collapse
Affiliation(s)
- Caroline Hilmi
- Institut National de la Santé et de la Recherche Médicale U597, Biologie et Pathologie des cellules mélanocytaires: de la pigmentation cutanée au mélanome, Nice, France
| | | | | | | | | | | | | |
Collapse
|
18
|
Beuret L, Flori E, Denoyelle C, Bille K, Busca R, Picardo M, Bertolotto C, Ballotti R. Up-regulation of MET Expression by α-Melanocyte-stimulating Hormone and MITF Allows Hepatocyte Growth Factor to Protect Melanocytes and Melanoma Cells from Apoptosis. J Biol Chem 2007; 282:14140-7. [PMID: 17371876 DOI: 10.1074/jbc.m611563200] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The MET proto-oncogene encodes for the hepatocyte growth factor (HGF) receptor, a plasma membrane tyrosine kinase that is involved in melanocyte growth and melanoma development. In mouse melanoma cells, Met expression is increased by alphaMSH via the activation of the cAMP pathway. However, the mechanism by which cAMP regulates MET and the biological consequences of this increase were not known. In the present report, we show that alphaMSH regulates MET expression in both human melanocytes and mouse melanoma cells through a transcriptional mechanism that requires MITF. Furthermore, the adenovirus driven expression of MITF is sufficient to increase MET in melanoma cells. Functional analysis of the MET promoter allows us to identify an E-box motif conserved in both human and mouse promoter that mediates the effect of MITF. Interestingly, up-regulation of MET expression by cAMP leads to an exacerbated HGF signaling and allows HGF to protect melanocytes and melanoma cells from apoptosis. Thus, physiological stimuli or pathological events that would induce MITF expression may lead to increased MET expression thereby favoring melanoma survival. These observations strengthen the roles of MITF and MET in melanoma development.
Collapse
Affiliation(s)
- Laurent Beuret
- INSERM, U597, Biologie et Pathologies des Cellules Mélanocytaires: de la Pigmentation Cutanée au Mélanome, Equipe labellisée par la Ligue Nationale contre le Cancer, Nice Cedex 2, France
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Larribere L, Khaled M, Tartare-Deckert S, Busca R, Luciano F, Bille K, Valony G, Eychene A, Auberger P, Ortonne JP, Ballotti R, Bertolotto C. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 2005; 11:1084-91. [PMID: 15243584 DOI: 10.1038/sj.cdd.4401475] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Melanocytes are cells of the epidermis that synthesize melanin, which is responsible for skin pigmentation. Transformation of melanocytes leads to melanoma, a highly aggressive neoplasm, which displays resistance to apoptosis. In this report, we demonstrate that TNF-related apoptosis-inducing ligand (TRAIL), which was thought to kill only transformed cells, promotes very efficiently apoptosis of primary human melanocytes, leading to activation of caspases 8, 9 and 3, and the cleavage of vital proteins. Further, we show that stem cell factor (SCF), a physiologic melanocyte growth factor that activates both the phosphatidyl-inositol-3 kinase (PI3K) and the extracellular regulated kinase (ERK) pathways, strongly protects melanocytes from TRAIL and staurosporine killing. Interestingly, inhibition of PI3K or its downstream target AKT completely blocks the antiapoptotic effect of SCF, while inhibition of ERK has only a moderate effect. Our data indicate that protection evoked by SCF/PI3K/AKT cascade is not mediated by an increase in the intracellular level of FLIP. Further, only a sustained PI3K activity can protect melanocytes from apoptosis, thereby indicating that the PI3K/AKT pathway plays a pivotal role in melanocyte survival. The results gathered in this report bring new information on the molecular mechanisms involved in primary melanocyte apoptosis and survival that would help to better understand the process by which melanomas acquire their resistance to apoptosis.
Collapse
Affiliation(s)
- L Larribere
- INSERM U597, Biologie et pathologie des cellules mélanocytaires: de la pigmentation cutanée aux mélanomes, Equipe labellisée par la Ligue Nationale contre le Cancer, 28, avenue de Valombrose, 06107 Nice Cedex 2, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Larribere L, Hilmi C, Khaled M, Gaggioli C, Bille K, Auberger P, Ortonne JP, Ballotti R, Bertolotto C. The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 2005; 19:1980-5. [PMID: 16140982 PMCID: PMC1199569 DOI: 10.1101/gad.335905] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Microphthalmia-associated transcription factor (MITF) M-form is a melanocyte-specific transcription factor that plays a key role in melanocyte development, survival, and differentiation. Here, we identified MITF as a new substrate of caspases and we characterized the cleavage site after Asp 345 in the C-terminal domain. We show that expression of a noncleavable form of MITF renders melanoma cells resistant to apoptotic stimuli, and we found that the C-terminal fragment generated upon caspase cleavage is endowed with a proapoptotic activity that sensitizes melanoma cells to death signals. The proapoptotic function gained by MITF following its processing by caspases provides a tissue-restricted means to modulate death in melanocyte and melanoma cells.
Collapse
Affiliation(s)
- Lionel Larribere
- INSERM U597, Biologie et Pathologie des cellules mélanocytaires: de la pigmentation cutanée aux mélanomes, Ligue Nationale contre le Cancer, Equipe labellisée 2001, 06107 NICE Cedex 2, France
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Buscà R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribère L, Bertolotto C, Virolle T, Barbry P, Pouysségur J, Ponzio G, Ballotti R. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. ACTA ACUST UNITED AC 2005; 170:49-59. [PMID: 15983061 PMCID: PMC2171372 DOI: 10.1083/jcb.200501067] [Citation(s) in RCA: 130] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In melanocytes and melanoma cells α-melanocyte stimulating hormone (α-MSH), via the cAMP pathway, elicits a large array of biological responses that control melanocyte differentiation and influence melanoma development or susceptibility. In this work, we show that cAMP transcriptionally activates Hif1a gene in a melanocyte cell–specific manner and increases the expression of a functional hypoxia-inducible factor 1α (HIF1α) protein resulting in a stimulation of Vegf expression. Interestingly, we report that the melanocyte-specific transcription factor, microphthalmia-associated transcription factor (MITF), binds to the Hif1a promoter and strongly stimulates its transcriptional activity. Further, MITF “silencing” abrogates the cAMP effect on Hif1a expression, and overexpression of MITF in human melanoma cells is sufficient to stimulate HIF1A mRNA. Our data demonstrate that Hif1a is a new MITF target gene and that MITF mediates the cAMP stimulation of Hif1a in melanocytes and melanoma cells. Importantly, we provide results demonstrating that HIF1 plays a pro-survival role in this cell system. We therefore conclude that the α-MSH/cAMP pathway, using MITF as a signal transducer and HIF1α as a target, might contribute to melanoma progression.
Collapse
Affiliation(s)
- Roser Buscà
- INSERM U597, Biologie et physiopathologie des cellules mélanocytaires, Faculty of Medicine, 06107 Nice cedex 2, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Passeron T, Bahadoran P, Bertolotto C, Chiaverini C, Buscà R, Valony G, Bille K, Ortonne JP, Ballotti R. Cyclic AMP promotes a peripheral distribution of melanosomes and stimulates melanophilin/Slac2-a and actin association. FASEB J 2004; 18:989-91. [PMID: 15059972 DOI: 10.1096/fj.03-1240fje] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Melanosomes are melanin-containing organelles that belong to a recently individualized group of lysosome-related organelles. Recently, numerous reports have dissected the molecular mechanisms that control melanosome transport, but nothing was known about the possible regulation of melanosome distribution by exogenous physiological stimulus. In the present report, we demonstrate that a physiological melanocyte-differentiating agent such as alpha-melanocyte-stimulating hormone, through the stimulation of the cAMP pathway, induces a rapid centrifugal transport of melanosomes, leading to their accumulation at the dendrite tips of melanocytes. Interestingly, the small GTP binding proteins of the p21Rho family and one of their effectors, p160 Rho-associated kinase, but not PKA, play a key role in redistribution of melanosomes at the extremities of the dendrites. Further, we have investigated, at the molecular level, the effect of cAMP on the different proteins involved in the control of melanosome transport. We demonstrate that cAMP stimulates the expression of Rab27a and rapidly increases the interaction of the melanophilin/Slac2-a with actin. Thus, we propose that the stimulation of the interaction between melanophilin/Slac2-a and actin would allow the rapid accumulation of melanosomes in the actin-rich region of the dendrite extremities.
Collapse
Affiliation(s)
- Thierry Passeron
- INSERM U597, Biologie et Pathologie des Celllules Mélanocytaires, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Khaled M, Larribere L, Bille K, Ortonne JP, Ballotti R, Bertolotto C. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol 2003; 121:831-6. [PMID: 14632202 DOI: 10.1046/j.1523-1747.2003.12420.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In B16 melanoma cells, cyclic adenosine monophosphate inhibits the phosphatidylinositol-3-kinase and the phosphatidylinositol-3-kinase inhibitor, LY294002, stimulates melanogenesis. However, the molecular mechanisms, by which phosphatidylinositol-3-kinase inhibition increases melanogenesis remained to be identified. In this study, we show that LY294002 up-regulates the expression of the melanogenic enzymes, tyrosinase and Tyrp1, through a transcriptional mechanism that involves microphthalmia associated transcription factor, a basic helix-loop-helix transcription factor, which plays a key role in melanocyte survival and differentiation. Further, we observe that LY294002 increases the intracellular content of microphthalmia associated transcription factor, thereby demonstrating that microphthalmia associated transcription factor is also a convergence point of the phosphatidylinositol-3-kinase signaling pathway. Finally, our results indicate that LY294002 controls microphthalmia associated transcription factor at the transcriptional level through distal regulatory element that remain to be identified. Interestingly, we have recently reported that cAMP-elevating agents, through a phosphatidylinositol-3-kinase/AKT inhibition and a glycogen synthase kinase 3beta activation, may stimulate microphthalmia associated transcription factor binding to its target sequence, suggesting that inhibition of the phosphatidylinositol-3-kinase is implicated in the stimulation of melanogenesis at different levels. Thus, the results presented in this report strengthen the importance of the phosphatidylinositol-3-kinase pathway in the regulation of melanogenesis and emphasize the complexity of the cyclic adenosine monophosphate signaling that controls melanocyte differentiation and melanogenesis.
Collapse
Affiliation(s)
- Mehdi Khaled
- INSERM U385, Biologie et Physiopathologie de la Peau, Nice, France
| | | | | | | | | | | |
Collapse
|
24
|
Khaled M, Larribere L, Bille K, Ortonne JP, Ballotti R, Bertolotto C. SP-04 Microphthalmia associated transcription factor (mitf) is a target of the pi3k pathway. ACTA ACUST UNITED AC 2003. [DOI: 10.1034/j.1600-0749.2003.08312.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
25
|
Bahadoran P, Busca R, Chiaverini C, Westbroek W, Lambert J, Bille K, Valony G, Fukuda M, Naeyaert JM, Ortonne JP, Ballotti R. Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome. J Biol Chem 2003; 278:11386-92. [PMID: 12531900 DOI: 10.1074/jbc.m211996200] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Rab27a plays a pivotal role in the transport of melanosomes to dendrite tips of melanocytes and mutations in RAB27A, which impair melanosome transport cause the pigmentary dilution and the immune deficiency found in several patients with Griscelli syndrome (GS). Interestingly, three GS patients present single homozygous missense mutations in RAB27A, leading to W73G, L130P, and A152P transitions that affect highly conserved residues among Rab proteins. However, the functional consequences of these mutations have not been studied. In the present report, we evaluated the effect of overexpression of these mutants on melanosome, melanophilin, and myosin-Va localization in B16 melanoma cells. Then we studied several key parameters for Rab27a function, including GTP binding and interaction with melanophilin/myosin-Va complex, which links melanosomes to the actin network. Our results showed that Rab27a-L130P cannot bind GTP, does not interact with melanophilin, and consequently cannot allow melanosome transport on the actin filaments. Interestingly, Rab27a-W73G binds GTP but does not interact with melanophilin. Thus, Rab27a-W73G cannot support the actin-dependent melanosome transport. Finally, Rab27a-A152P binds both GTP and melanophilin. However, Rab27a-A152P does not allow melanosome transport and acts as a dominant negative mutant, because its overexpression, in B16 melanoma cells, mimics a GS phenotype. Hence, the interaction of Rab27a with melanophilin/myosin-Va is not sufficient to ensure a correct melanosome transport. Our results pointed to an unexpected complexity of Rab27a function and open the way to the search for new Rab27a effectors or regulators that control the transport of Rab27a-dependent vesicles.
Collapse
Affiliation(s)
- Philippe Bahadoran
- INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, Avenue de Valombrose, 06107, Nice cedex 2, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Khaled M, Larribere L, Bille K, Aberdam E, Ortonne JP, Ballotti R, Bertolotto C. Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem 2002; 277:33690-7. [PMID: 12093801 DOI: 10.1074/jbc.m202939200] [Citation(s) in RCA: 134] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In human and mouse, cAMP plays a key role in the control of pigmentation. cAMP, through the activation of protein kinase A, increases the expression of microphthalmia-associated transcription factor (MITF), which in turn stimulates tyrosinase gene expression, to allow melanin synthesis. Beyond this simplified scheme, cAMP inhibits phosphatidylinositol 3-kinase (PI3K), and inhibition of PI3K, by a specific inhibitor, stimulates melanogenesis. However, the link between the PI3K pathway and melanogenesis remained to be elucidated. In this report, we showed that cAMP, through a protein kinase A-independent mechanism, led to inhibition of AKT phosphorylation and activity. Consistent with the role of AKT in the regulation of glycogen synthase kinase 3beta (GSK3beta), cAMP decreased the phosphorylation of GSK3beta and stimulated its activity. Further, experiments were performed to investigate the role of GSK3beta in the regulation of MITF expression and function. We observed that GSK3beta regulated neither MITF promoter activity nor the intrinsic transcriptional activity of MITF but synergized with MITF to activate the tyrosinase promoter. Additionally, lithium, a GSK3beta inhibitor, impaired the response of the tyrosinase promoter to cAMP, and cAMP increased the binding of MITF to the M-box. Taking into account that GSK3beta phosphorylates MITF and increases the ability of MITF to bind its target sequence, our results indicate that activation of GSK3beta by cAMP facilitates MITF binding to the tyrosinase promoter, thereby leading to stimulation of melanogenesis.
Collapse
Affiliation(s)
- Mehdi Khaled
- INSERM U385, Biologie et Physiopathologie de la peau, IFR 50, 28 avenue de Valombrose, 06107 NICE Cedex 2, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Bahadoran P, Aberdam E, Mantoux F, Buscà R, Bille K, Yalman N, de Saint-Basile G, Casaroli-Marano R, Ortonne JP, Ballotti R. Rab27a: A key to melanosome transport in human melanocytes. J Cell Biol 2001; 152:843-50. [PMID: 11266474 PMCID: PMC2195788 DOI: 10.1083/jcb.152.4.843] [Citation(s) in RCA: 185] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Normal pigmentation depends on the uniform distribution of melanin-containing vesicles, the melanosomes, in the epidermis. Griscelli syndrome (GS) is a rare autosomal recessive disease, characterized by an immune deficiency and a partial albinism that has been ascribed to an abnormal melanosome distribution. GS maps to 15q21 and was first associated with mutations in the myosin-V gene. However, it was demonstrated recently that GS can also be caused by a mutation in the Rab27a gene. These observations prompted us to investigate the role of Rab27a in melanosome transport. Using immunofluorescence and immunoelectron microscopy studies, we show that in normal melanocytes Rab27a colocalizes with melanosomes. In melanocytes isolated from a patient with GS, we show an abnormal melanosome distribution and a lack of Rab27a expression. Finally, reexpression of Rab27a in GS melanocytes restored melanosome transport to dendrite tips, leading to a phenotypic reversion of the diseased cells. These results identify Rab27a as a key component of vesicle transport machinery in melanocytes.
Collapse
Affiliation(s)
- Philippe Bahadoran
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Edith Aberdam
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Frédéric Mantoux
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Roser Buscà
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Karine Bille
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Nevin Yalman
- Istanbûl School of Medicine, Pediatric Hematology/Oncology, 34390 Istanbul, Turkey
| | - Geneviève de Saint-Basile
- Unité de Recherches sur le Développement Normal et Pathologique du Système Immunitaire, Institut National de la Santé et de la Recherche Médicale U429, Hôpital Necker, 75743 Paris Cedex 15, France
| | | | - Jean-Paul Ortonne
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| | - Robert Ballotti
- Unité de Recherches sur la Biologie et la Physiopathologie de la Peau, Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice Cedex 2, France
| |
Collapse
|
28
|
Verastegui C, Bille K, Ortonne JP, Ballotti R. Regulation of the microphthalmia-associated transcription factor gene by the Waardenburg syndrome type 4 gene, SOX10. J Biol Chem 2000; 275:30757-60. [PMID: 10938265 DOI: 10.1074/jbc.c000445200] [Citation(s) in RCA: 134] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The absence of melanocytes from the cochlea and epidermis is responsible of deafness and hypopigmentation, two symptoms shared by the four Waardenburg syndrome (WS) subtypes. Microphthalmia-associated transcription factor (MITF) controls melanocyte survival and differentiation. Mutations, which impair MITF function or expression, result in an abnormal melanocyte development leading to the WS2. WS1 and WS3 are caused by mutation in the gene encoding the transcription factor Pax3, which regulates MITF expression. Recently, mutations in SOX10, a gene encoding a SRY-related transcription factor, have been reported in patients with WS4. However, the molecular basis of the defective melanocyte development in these patients remained to be elucidated. In the present report, we demonstrate that Sox10 is a strong activator of the MITF promoter, and we identify a Sox10 binding site between -264 and -266 of the MITF promoter. Finally, we show that three SOX10 mutations found in WS4 abolish the transcriptional activity of the resulting Sox10 proteins toward the MITF promoter. Taken together, our observations bring new and meaningful information concerning the molecular process that leads to a defective melanocyte development in WS4 patients with SOX10 mutations.
Collapse
Affiliation(s)
- C Verastegui
- INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, Avenue de Valombrose, Nice, 06107 Cedex, France
| | | | | | | |
Collapse
|
29
|
Verastegui C, Bertolotto C, Bille K, Abbe P, Ortonne JP, Ballotti R. TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and TyrpI genes. Mol Endocrinol 2000; 14:449-56. [PMID: 10707962 DOI: 10.1210/mend.14.3.0428] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Microphthalmia gene encodes a basic helix-loop-helix-leucine zipper (bHLH-Zip) transcription factor involved in the development of the melanocyte lineage and plays a key role in the transcriptional regulation of the melanogenic enzymes, tyrosinase and TyrpI. Recently, we have shown that Microphthalmia mediates the melanogenic effects elicited by alphaMSH that up-regulates the expression of tyrosinase through the activation of the cAMP pathway. Therefore, Microphthalmia appears as a principal gene in melanocyte development and functioning. Among the transcription factors of the bHLH-Zip family, TFE3 and TFEB show a remarkably elevated homology with Microphthalmia. These observations prompted us to investigate the role of TFE3 and TFEB in the regulation of tyrosinase and TyrpI gene transcription. We show in this report that overexpression of TFE3 stimulates the tyrosinase and TyrpI promoter activities, while TFEB acts only on the TyrpI promoter. TFE3 and TFEB elicit their effects mainly through the binding to Mbox (AGTCATGTGCT) and Ebox motifs (CATGTG) of tyrosinase and TyrpI promoters. In B16 melanoma cells, the high basal expression of TFE3 is down-regulated by forskolin and by alphaMSH. Interestingly, endogenous TFE3 cannot bind as homodimers to the Mbox, and we did not detect TFE3/Mi heterodimers. According to these data, TFE3 is clearly endowed with the capacity to regulate tyrosinase and TyrpI gene expression. However, TFE3 binding to the melanogenic gene promoters is hindered, thereby preventing its potential melanogenic action. In specific physiological or pathological conditions, the recovery of its binding function would make TFE3 an important element in melanogenesis regulation.
Collapse
Affiliation(s)
- C Verastegui
- Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, Nice, France
| | | | | | | | | | | |
Collapse
|
30
|
Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, Ballotti R. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998; 142:827-35. [PMID: 9700169 PMCID: PMC2148160 DOI: 10.1083/jcb.142.3.827] [Citation(s) in RCA: 376] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/1998] [Revised: 07/01/1998] [Indexed: 02/08/2023] Open
Abstract
Melanocyte differentiation characterized by an increased melanogenesis, is stimulated by alpha-melanocyte-stimulating hormone through activation of the cAMP pathway. During this process, the expression of tyrosinase, the enzyme that controls melanin synthesis is upregulated. We previously showed that cAMP regulates transcription of the tyrosinase gene through a CATGTG motif that binds microphthalmia a transcription factor involved in melanocyte survival. Further, microphthalmia stimulates the transcriptional activity of the tyrosinase promoter and cAMP increases the binding of microphthalmia to the CATGTG motif. These observations led us to hypothesize that microphthalmia mediates the effect of cAMP on the expression of tyrosinase. The present study was designed to elucidate the mechanism by which cAMP regulates microphthalmia function and to prove our former hypothesis, suggesting that microphthalmia is a key component in cAMP-induced melanogenesis. First, we showed that cAMP upregulates the transcription of microphthalmia gene through a classical cAMP response element that is functional only in melanocytes. Then, using a dominant-negative mutant of microphthalmia, we demonstrated that microphthalmia is required for the cAMP effect on tyrosinase promoter. These findings disclose the mechanism by which cAMP stimulates tyrosinase expression and melanogenesis and emphasize the critical role of microphthalmia as signal transducer in cAMP-induced melanogenesis and pigment cell differentiation.
Collapse
Affiliation(s)
- C Bertolotto
- Institut National de la Sante et de la Recherche Medicale U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, Paris, France
| | | | | | | | | | | | | |
Collapse
|
31
|
Bertolotto C, Bille K, Ortonne JP, Ballotti R. In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter. Oncogene 1998; 16:1665-70. [PMID: 9582014 DOI: 10.1038/sj.onc.1201685] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In B16 melanoma cells, cAMP-induced melanogenesis is inhibited by the tumor promoting phorbol ester, TPA. However, the role of PKC activation or depletion in the inhibition of melanogenesis by TPA remains controversial. In this report, using specific PKC inhibitors, we demonstrated that PKC inhibition does not impair cAMP-induced melanin synthesis and tyrosinase expression. Further, the inhibition of melanogenesis by TPA results from a decrease of the tyrosinase promoter transcriptional activity and this effect is mimicked by over-expression of a constitutively active form of PKC alpha. These findings clearly demonstrate that PKC activation accounts for the inhibition of melanin synthesis by TPA. Additional experiments were undertaken to elucidate the mechanism by which TPA inhibits the tyrosinase gene transcription. Deletions and mutation in the tyrosinase promoter showed that TPA acts on a M-box which is involved in tissue-specific expression and regulation by cAMP of the tyrosinase gene. We showed that TPA decreases the binding of microphthalmia, a basic helix-loop-helix transcription factor, to the M-box. Since microphthalmia, strongly stimulates the transcriptional activity of the promoter we propose that TPA, through PKC activation, decreases microphthalmia binding to the M-box of the tyrosinase promoter, thereby leading to a reduced tyrosinase expression and melanogenesis inhibition.
Collapse
Affiliation(s)
- C Bertolotto
- INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, France
| | | | | | | |
Collapse
|
32
|
Bertolotto C, Buscà R, Abbe P, Bille K, Aberdam E, Ortonne JP, Ballotti R. Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. Mol Cell Biol 1998; 18:694-702. [PMID: 9447965 PMCID: PMC108780 DOI: 10.1128/mcb.18.2.694] [Citation(s) in RCA: 264] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
In melanocytes and in melanoma cells, cyclic AMP (cAMP)-elevating agents stimulate melanogenesis and increase the transcription of tyrosinase, the rate-limiting enzyme in melanin synthesis. However, two other enzymes, tyrosinase-related protein 1 (TRP1) and TRP2, are required for a normal melanization process leading to eumelanin synthesis. In B16 melanoma cells, we demonstrated that stimulation of melanogenesis by cAMP-elevating agents results in an increase in tyrosinase, TRP1, and TRP2 expression. cAMP, through a cAMP-dependent protein kinase pathway, stimulates TRP1 and TRP2 promoter activities in both B16 mouse melanoma cells and normal human melanocytes. Regulation of the TRP1 and TRP2 promoters by cAMP involves a M box and an E box. Further, a classical cAMP response element-like motif participates in the cAMP responsiveness of the TRP2 promoter, demonstrating that the TRP2 gene is subjected to different regulatory processes, which could account for its different expression patterns during embryonic development or under specific physiological and pathological conditions. We also found that microphthalmia, a basic helix-loop-helix transcription factor, strongly stimulates the transcriptional activities of the TRP1 and TRP2 promoters, mainly through binding to the M boxes. Additionally, we demonstrated that cAMP increases microphthalmia expression and thereby its binding to TRP1 and TRP2 M boxes. These convergent and compelling results disclose at least a part of the molecular mechanism involved in the regulation of melanogenic gene expression by cAMP and emphasize the pivotal role of microphthalmia in this process.
Collapse
Affiliation(s)
- C Bertolotto
- INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | |
Collapse
|
33
|
Bertolotto C, Bille K, Ortonne JP, Ballotti R. Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: implication of the microphthalmia gene product. J Biophys Biochem Cytol 1996; 134:747-55. [PMID: 8707852 PMCID: PMC2120943 DOI: 10.1083/jcb.134.3.747] [Citation(s) in RCA: 116] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
In melanocytes and in melanoma cells, upregulation of melanogenesis, by cAMP elevating agents, results from a stimulation of tyrosinase activity that has been ascribed to an increase in tyrosinase protein and messenger amount. However, the mechanism by which cAMP elevating agents increase tyrosinase mRNA remains to be elucidated. In this study, using a luciferase reporter plasmid containing the 2.2-kb fragment 5' of the transcriptional start site of the mouse tyrosinase gene, we showed that cAMP elevating agents lead to a strong stimulation (20-fold) of transcriptional activity of the tyrosinase promoter. Deletions and mutations in the mouse tyrosinase promoter showed that the M-box 70-bp upstream from the TATA-box and the E-box located downstream the TATA-box, near to the initiator site, are involved in the regulation of the tyrosinase promoter activity by cAMP. Additionally, we showed that microphthalmia, a b-HLH transcription factor associated with pigmentation disorders in mouse, binds to these regulatory elements and modulates the transcriptional activity of the tyrosinase promoter. Since cAMP stimulates the binding of microphthalmia to the M-box and to the E-box; it is tempting to propose that microphthalmia, through its interaction with cis-acting elements surrounding the TATA-box, plays a key role in the regulation of the mouse tyrosinase gene expression by cAMP.
Collapse
Affiliation(s)
- C Bertolotto
- Institut National de la Santé et de la Recherche Médicale (INSERM) U 385, Faculté de Médecine, Nice, France
| | | | | | | |
Collapse
|
34
|
Jorgensen SH, Bille K. [What is nursing?]. Sygeplejersken 1974; 74:11. [PMID: 4499095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|